行情

EARS

EARS

Auris Medical Holding Ltd
NASDAQ

实时行情|Nasdaq Last Sale

1.490
+0.020
+1.36%
交易中 13:15 01/24 EST
开盘
1.490
昨收
1.470
最高
1.520
最低
1.477
成交量
5.37万
成交额
--
52周最高
9.50
52周最低
1.300
市值
3,587.53万
市盈率(TTM)
-0.2128
分时
5日
1月
3月
1年
5年

分析师评级

1位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

EARS 新闻

  • 午盘:制造业PMI不及预期 美股下跌道指跌近100点
  • 新浪美股.1小时前
  • 数据显示Apple TV+四季度美国订阅用户达3360万
  • 新浪美股.1小时前
  • 迪斯尼+大获成功 大摩上调迪士尼目标价至170美元
  • 新浪美股.2小时前
  • 尚乘蔡志坚:数字化将进一步推动可持续发展
  • 新浪财经.2小时前

更多

所属板块

生物技术和医学研究
-2.09%
制药与医学研究
-1.58%

热门股票

名称
价格
涨跌幅

EARS 简况

Auris Medical Holding AG is a Switzerland-based biotechnology company engaged in developing pharmaceutical products for the treatment of inner ear disorders and mental health supportive care. The Company focuses on the development of intranasal betahistine for the treatment of vertigo (AM-125) and for the treatment of antipsychotic-induced weight gain and somnolence (AM-201). The betahistine program is in Phase 1 of clinical trials. Other programs in the Company's product pipeline include brimapitide-based AM-111 for the treatment of acute inner ear hearing loss and eskatemine-based Keyzilen (AM-101) for the treatment of acute inner ear tinnitus, both in Phase 3 of clinical trials, as well as AM-102 indicated for tinnitus, undergoing preclinical studies focused on selecting the lead compound. The Company operates through subsidiaries in Switzerland, Ireland and the United States.
展开

Webull提供Auris Medical Holding Ltd的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。